GRDN - NYSE

Guardian Pharmacy Services, Inc.

GRDN·NYSE

$39.14

-0.31%

HealthcareMedical - Distribution

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.48B

EPS0.7900

P/E Ratio49.54

Earnings Date08/10/2026

412.66M

Assets

29%

3Y+61.0%

5Y+89.0%

10Y+127.0%

194.73M

Total Liabilities

14%

3Y+8.0%

5Y+29.0%

10Y+71.0%

217.92M

Total Equity

45%

3Y+187.0%

5Y+225.0%

10Y+264.0%

Guardian Pharmacy Services, Inc. Funding & Solvency Profile

GRDN · NYSE

Current Assets

Cash & Cash Equivalents65.62M

Net Receivables101.61M

Inventory43.36M

Other Current Assets11.04M

Total Current Assets222 M

Non-Current Assets

Property, Plant & Equipment90.17M

Goodwill & Intangible Assets98.22M

Long-Term Investments0.00

Other Non-Current Assets436.00K

Total Non-Current Assets91 M

Total Assets

412.66M

Financial Health Analysis

Current Ratio

1.38x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Debt-to-Equity Ratio

0.89x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

61 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

54% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Guardian Pharmacy Services, Inc. Balance Sheet

GRDN • NYSE

Guardian Pharmacy Services, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	65.6M	4.7M	752K	607K	15M	6.4M	275K	2.3M
Cash & Short-Term Investments	65.6M	4.7M	752K	607K	15M	6.4M	275K	2.3M
Net Receivables	101.6M	97.2M	77.3M	67.8M	55.2M	45.8M	54.2M	47.7M
Accounts Receivables	101.6M	97.2M	77.3M	67.8M	55.2M	45.8M	50.9M	44.9M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	3.3M	2.7M
Inventory	43.4M	40.6M	36.7M	41.4M	33.1M	31.9M	30.9M	27.5M
Prepaids	0.0	0.0	0.0	0.0	0.0	6.8M	0.0	0.0
Other Current Assets	11M	9.6M	14.9M	10.1M	8.5M	2.9M	4.7M	3.8M
Total Current Assets	221.6M	152M	129.6M	120M	111.9M	93.8M	90.1M	81.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	90.2M	79M	73.2M	65.2M	51.7M	52M	35.4M	28M
Goodwill	79.7M	69.3M	56M	56M	54.6M	52.5M	46.3M	47.8M
Intangible Assets	18.5M	14.9M	12M	14.4M	17.1M	19.1M	20.7M	23.8M
Goodwill & Intangible Assets	98.2M	84.2M	68M	70.5M	71.7M	71.6M	67M	71.6M
Tax Assets	2.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	436K	5.7M	358K	435K	529K	505K	4M	953K
Total Non-Current Assets	191M	168.8M	141.6M	136.1M	124M	124M	106.4M	100.6M
Total Assets	412.7M	320.8M	271.2M	256.1M	235.9M	217.9M	196.5M	181.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	116.2M	102.4M	85.6M	78.1M	64.6M	53.4M	54.9M	47.5M
Accounts Payable	116.2M	102.4M	85.6M	78.1M	64.6M	53.4M	54.9M	47.5M
Accrued Expenses	0.0	14.4M	17M	13.9M	14.6M	20.4M	5.5M	5.1M
Short Term Debt	7.2M	0.0	13M	8M	3.7M	3.6M	17M	2.6M
Capital Lease Obligations (Current)	7.2M	10.6M	10.1M	8.4M	8.2M	8.9M	2.8M	2.4M
Other Current Liabilities	30.2M	16.7M	12.3M	3.6M	20.4M	0.0	9.9M	7.7M
Total Current Liabilities	160.7M	144.1M	138M	112M	111.5M	86.4M	90.2M	65.3M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	19M	23M	27M	30.7M	33.7M	36.4M
Other Non-Current Liabilities	337K	0.0	27.3M	21.5M	27.9M	18.2M	12M	9.8M
Total Non-Current Liabilities	34M	26.7M	73.3M	68.2M	71M	64.4M	49.3M	48.5M
Capital Lease Obligations	40.8M	37.3M	37.2M	32.1M	24.3M	24.5M	6.4M	4.7M
Total Liabilities	194.7M	170.8M	211.3M	180.2M	182.5M	150.8M	139.5M	113.8M
SHAREHOLDERS' EQUITY
Common Stock	63K	63K	28.2M	42.7M	24.1M	39.2M	30M	34M
Additional Paid-In Capital	139.4M	125.5M	0.0	0.0	0.0	0.0	0.0	0.0
Retained Earnings	66.3M	17.1M	0.0	0.0	0.0	0.0	0.0	0.0
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	-185K	-676K	-630K	-386K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-29.3M	386K
Total Stockholders' Equity	205.8M	142.7M	28.2M	42.7M	23.9M	38.5M	0.0	34M
Total Equity	217.9M	150M	59.9M	75.9M	53.3M	67.1M	27.7M	59.9M
Minority Interest	12.2M	7.3M	31.7M	33.2M	29.4M	28.6M	27.7M	25.9M
SUMMARY
Total Liabilities & Equity	430.8M	320.8M	271.2M	256.1M	235.9M	217.9M	139.5M	147.8M
Total Debt	44.7M	37.3M	69.2M	63M	55M	58.8M	57.1M	43.7M
Net Debt	-20.9M	32.7M	68.4M	62.4M	40M	52.4M	56.8M	41.5M
Shares Outstanding	63,356,902	63,356,902	63,356,902	63,356,902	63,356,902	63,356,902	63,356,902	63,356,902

SEC Filings

GRDN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 28, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 26, 2026	May 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 23, 2026	March 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 11, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing

Showing 1 to 10 of 35 filings

Related Guides

Blog Categories

Continue your GRDN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.